HEMISPHERX BIOPHARMA has a total of 23 patent applications. Its first patent ever was published in 2002. It filed its patents most often in United States, China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are BESTEWIL HOLDING BV, WANK RUDOLF and ALTIMMUNE INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | China | 4 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Canada | 3 | |
#5 | WIPO (World Intellectual Property Organization) | 3 | |
#6 | Australia | 1 | |
#7 | Japan | 1 | |
#8 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Carter William A | 19 |
#2 | Strayer David | 16 |
#3 | Strayer David R | 3 |
#4 | David Strayer | 2 |
#5 | David Carter William A Strayer | 1 |
#6 | Carter William | 1 |
Publication | Filing date | Title |
---|---|---|
CN101437534A | Broad spectrum immune and antiviral gene modulation by oral interferon | |
WO2007067517A2 | Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants | |
CN101410133A | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants | |
US2006035859A1 | Treating severe and acute viral infections | |
AU2002364163A8 | Use of dsrnas in strategic therapeutic intervention of highly active antiretroviral therapy |